Full Press Release Details
InMed to Present at the Emerging Growth Conference
Vancouver, BC - June 10, 2024 - InMed
Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM), a clinical stage pharmaceutical company focused
on developing a pipeline of proprietary small molecule drug candidates, today announced the
Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024.
InMed's CEO, Mr. Eric A. Adams, will present
a corporate overview followed by a questions and answers session. Presentation details are as follows:
InMed's presentation at Emerging Growth
If attendees are not able to join the event live on the day of the
conference, an archived webcast will also be made available on EmergingGrowth.com, Emerging Growth YouTube Channel or InMed's investor
relations events page.
Pharmaceuticals is a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates
targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular
and dermatological indications. Together with its subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization
of rare cannabinoids and proprietary cannabinoid analogs. For more information, visit www.inmedpharma.com.
About the Emerging Growth Conference
The Emerging Growth conference is an effective
way for public companies to present and communicate their new products, services and other major announcements to the investment community
from the convenience of their office, in a time efficient manner.
The Conference focus and coverage includes companies
in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and
the overall potential for long term growth. Its audience includes potentially tens of thousands of Individual and Institutional investors,
as well as Investment advisors and analysts.
Vice President, Investor Relations
and Corporate Communications
Cautionary Note Regarding Forward-Looking Information:
This news release contains "forward-looking
information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning
of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects",
"anticipates", "believes", "intends", "potential", "possible", "would"
and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks,
uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's
current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Additionally, there are known and unknown risk
factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results,
performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks
and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K and other filings
with the Securities and Exchange Commission on www.sec.gov.
All forward-looking information herein is qualified
in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results,
events or developments, except as required by law.